27 results about "Non antibiotic" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses trichoderma asperellum TS7-1 capable of efficiently degrading macrolide antibiotics and application of the trichoderma asperellum TS7-1, and belongs to the technical field of microorganisms. The preservation number of the trichoderma asperellum TS7-1 is CGMCC (China General Microbiological Culture Collection Center) No. 41372. The Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the invention has high-efficiency degradation capability on various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), the removal rates of the Trichoderma asperellum TS7-1, roxithromycin and azithromycin in 36h all reach 85% or above, and the Trichoderma asperellum TS7-1 has high-concentration antibiotic tolerance, degradation rate and degradation spectrum obviously superior to those of other strains in the prior art. The trichoderma asperellum TS7-1 is directly separated from a natural soil body which is not polluted by antibiotics, has no animal and plant pathogenicity hidden danger, has no microbial toxicity to degradation products of macrolide antibiotics, avoids secondary pollution, and has excellent environmental safety.

The invention provides an alcohol extraction method of cortex phellodendri and application of the cortex phellodendri alcohol extract as a liniment.The invention relates to the technical field of medicine.The alcohol extraction method of cortex phellodendri is provided, the alcohol extract of cortex phellodendri is obtained through the extraction method, the bacteriostatic activity of the alcohol extract of cortex phellodendri on propionibacterium acnes is 1.56 mg / mL, and the bacteriostatic activity of the alcohol extract of cortex phellodendri is remarkably superior to that of other existing traditional Chinese medicine extraction bacteriostatic schemes; meanwhile, the invention provides the golden cypress alcohol extract liniment for inhibiting acnes, propionibacterium acnes are synergistically inhibited by reducing the protein expression levels of Src, Akt and mTOR in skin tissues and destroying the completeness of cell walls and cell membranes of the propionibacterium acnes, and the liniment is not added with a penetration enhancer, does not irritate the skin, is safer to use, and has a good application prospect. The formed medicine film reduces evaporation of moisture on the skin surface, the medicine is promoted to be slowly released through cuticle, an animal model verifies that acnes rapidly fade after 4 days, a non-antibiotic treatment scheme is provided for light and moderate acnes, and a better treatment effect is achieved.

The invention discloses a Ti < 3 > C < 2 > T < x > MXene-GQD nano composite material as well as a preparation method and application thereof, and relates to the technical field of composite material preparation. The method comprises the following steps: dissolving LiF in a hydrochloric acid solution, and adding Ti3AlC2 powder to prepare a colloidal solution; the preparation method comprises the following steps: dissolving citric acid in deionized water, and then carrying out hydrothermal carbonization to prepare a GQD solution; and mixing the colloidal solution and the GQD solution, and stirring to obtain the nano composite material. According to the invention, the Ti3C2Tx MXene two-dimensional lamellar structure is utilized to stabilize the GQD nanoparticles, so that the GQD nanoparticles are uniformly dispersed and are not easy to agglomerate, and the long-term uniformity is ensured; by utilizing the photothermal effect of Ti3C2Tx MXene and the photodynamic effect of GQD, the dual photoresponse antibacterial efficiency is realized, the infection of drug-resistant bacteria can be efficiently inhibited, a non-antibiotic way is provided for treating the drug-resistant bacteria, and the infection problem and the related postoperative pain problem are effectively controlled in practice.

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.

The application discloses a wound dressing and a preparation method and application thereof; the wound dressing comprises polymer flexible fibers and cobalt-iron layered double hydroxide nanosheets dispersed in the polymer flexible fibers; the cobalt-iron layered double hydroxide nanosheets contain a cobalt vacancy structure in a crystal lattice. The wound dressing has a strong "electron capture effect" due to the cobalt vacancy. The wound dressing can physically capture electrons on a respiratory transmission chain of a pathogenic bacterial cell membrane, interferes with transmembrane proton transfer and ATP synthesis, directly kills the bacteria through "metabolic starvation", and further has a broad-spectrum physical bactericidal function independent of antibiotics. The wound dressing has excellent superoxide dismutase-like and catalase-like activities, can long-acting capture and remove active oxygen such as superoxide anions and hydrogen peroxide in an inflammatory microenvironment of a wound, promotes macrophages to polarize to a M2 phenotype for promoting repair, and has anti-inflammatory and pro-angiogenic functions.

The invention relates to the field of biological medicine and immunology, in particular to preparation and application of an anti-staphylococcus aureus enterotoxin B antibody. A heavy chain variable region of the antibody SEB-A8 provided by the invention comprises CDR sequences as shown in SEQ ID NO: 1-3, a light chain variable region of the antibody SEB-A8 comprises CDR sequences as shown in SEQ ID NO: 9-11, and the antibody SEB-A8 has important application value in treatment, prevention or diagnosis of staphylococcus aureus infection. Experimental data show that the antibody can effectively neutralize the superantigen activity of SEB and significantly improve the survival rate of MRSA infected mice, has a dose-dependent protection effect, can be used as a non-antibiotic treatment strategy, is used for treatment of methicillin-resistant staphylococcus aureus infection, has great significance in controlling development of bacterial drug resistance, and has a broad application prospect. And a new research direction is provided for clinical anti-infection treatment.

The invention provides a preparation method of a high-temperature-resistant antibacterial sputum suction catheter, and belongs to the technical field of medical instruments. The preparation method comprises the following steps: quaternary ammonium salt chitosan is treated by chitosanase to obtain modified chitosan, polytetrahydrofuran, polyethylene glycol and diisocyanate react to obtain a prepolymer, the prepolymer, dimethylolpropionic acid and the modified chitosan react to obtain a polyurethane prepolymer, modified silane and the polyurethane prepolymer are mixed to obtain a mixed material, and the mixed material is dried to obtain a finished product. And performing extrusion molding on the mixture to obtain the high-temperature-resistant antibacterial sputum suction catheter. Hydrophilic groups in the modified silane and polyurethane polymer can reduce the friction force on the surface of the sputum suction catheter and reduce vascular endothelial injury; in addition, quaternary ammonium salt structures in the resveratrol and the modified chitosan can jointly destroy metabolism of bacteria to achieve a good antibacterial effect, and the combined non-antibiotic antibacterial strategy can delay generation of drug-resistant bacteria.

The invention discloses an application of a phthalocyanine compound and a delivery system thereof in preparation of an anti-clostridium difficile toxin drug, and discovers that phthalocyanine can specifically target TFPI, CSPG4 and FZD1, 2, 7 receptor binding domains of clostridium difficile toxin B (TcdB), and effectively inhibits binding of toxin and host cells. In-vitro experiments prove that the phthalocyanine (Phthalocyanine, Pc) can be used for remarkably relieving the cytopathy induced by TcdB and has no cytotoxicity. In order to improve the curative effect, an extracellular vesicle (S-EV) from saccharomyces boulardii is creatively adopted to construct a drug loading system S-EV-Pc, and the pH responsive intestinal targeted delivery of the drug is realized. Animal experiments show that the preparation can significantly improve the survival rate of infected gerbil to 100%, significantly improve diarrhea symptoms, reduce intestinal TcdB load and relieve tissue pathological damage. The invention discloses the potential of phthalocyanine as a non-antibiotic small molecule drug in treatment of clostridium difficile infection (CDI) for the first time, and provides a brand new strategy and an experimental basis for developing a novel anti-CDI preparation.

The present invention relates to a non-antibiotic antimicrobial composition, new uses and methods of medical treatment or prophylaxis. In particular, the present invention relates to a non-antibiotic antimicrobial composition comprising a zeolite and at least one member of the Lactobacilli genus for the treatment of a disease or a condition associated with or caused by Helicobacter spp such as Helicobacter pylori.

The invention relates to a preparation method and application of an angstrom silver antibacterial hydrogel. The invention belongs to the technical field of antibacterial materials, and discloses a modified starch coated silver ion slow-release gel composition which is prepared from easily available raw materials including a silver ion source, powder grafted acrylic acid, alpha-potato starch and the like. The composition can be used in non-antibiotic nursing drugs or disinfection products on the skin surface. The composition can keep the color characteristic for a long time after being refrigerated, and can keep the gel characteristic for a long time below 20 DEG C. Meanwhile, expanded production is easy, and related application requirements are met.

The subject invention provides a novel class of mixed-metal chalcogenide compounds exhibiting POD-like catalytic activity, efficient photothermal conversion under NIR irradiation, and broad-spectrum antimicrobial properties. The invention further provides hydrogel formulations incorporating these compounds in a polymeric matrix, as well as their use in a range of biomedical applications, such as treating infected wounds, preventing surgical site infections, and delivering localized, non-antibiotic antimicrobial therapy.

The application belongs to the technical field of biological medicine, and particularly relates to application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. The application provides application of (E)-BCI hydrochloride in preparation of the medicine for treating sepsis. (E)-BCI hydrochloride regulates a DRD1 gene through targeting, quiets an interferon stimulation storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a nerve activity gene, and provides a non-antibiotic dependent medicine for sepsis treatment from a new target point of regulating inflammation and immune balance, and is particularly suitable for systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.

The present invention discloses a fully human Hla monoclonal antibody against Staphylococcus aureus α-hemolysin and its application. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the antibody heavy chain are shown as SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; the amino acid sequences of the CDR1, CDR2, and CDR3 of the light chain variable region are shown as SEQ ID NO.4, SNN, and SEQ ID NO.6. The antibody can specifically bind to Staphylococcus aureus α-hemolysin or free α-hemolysin, and can be used for treating, preventing, or diagnosing Staphylococcus aureus infections, etc., and will become an important research direction in the field of "non-antibiotic" treatment of methicillin-resistant Staphylococcus aureus infections and controlling the development of drug resistance.

This invention relates to the fields of biomedicine and immunology, and particularly to the preparation and application of an anti-Staphylococcal enterotoxin B antibody. The antibody provided by this invention has a SEB-A8 heavy chain variable region containing CDR sequences as shown in SEQ ID NO:1-3, and a light chain variable region containing CDR sequences as shown in SEQ ID NO:9-11. It has significant application value in the treatment, prevention, and diagnosis of Staphylococcus aureus infections. Experimental data show that this antibody can effectively neutralize the superantigen activity of SEB, significantly improve the survival rate of MRSA-infected mice, and exhibit a dose-dependent protective effect. It can be used as a "non-antibiotic" treatment strategy for the treatment of methicillin-resistant Staphylococcus aureus infections, which is of great significance in controlling the development of bacterial resistance and provides a new research direction for clinical anti-infective therapy.

An apparatus is provided for a removable catheter visible light therapy system designed to deliver a non-antibiotic in vivo bactericidal treatment agent. A medical device assembly is provided for removably insertion into a catheter (36) having a lumen (30). The medical device assembly includes an electromagnetic radiation (EMR) source (26) for providing non-ultraviolet therapeutic EMR of sufficient intensity to inactivate one or more infectious agents and / or stimulate the growth of healthy cells to produce a healing effect, and a removable EMR conduction system (18) at least partially insertable into and removable from the lumen of the catheter. The EMR conduction system includes at least one optical element (14) that propagates the therapeutic EMR axially through an insertable elongate body (24). The elongate body can have an outer surface between the coupling end and the distal end (34) with at least one modification that allows the therapeutic EMR to radiate radially from the elongate body adjacent the modification. Such modification can be tapered along the outer surface.

The application discloses a preparation method of a nano-mineral composite enzyme against drug-resistant bacteria, and belongs to the technical field of antibacterial materials and functional nanomaterials. The steps comprise the following: mixing vanadium-manganese nano-enzyme precursor powder prepared by taking ammonium metavanadate and a manganese source as raw materials with natural montmorillonite to prepare in-situ loaded composite precursor powder, and then calcining the composite precursor powder to obtain the nano-mineral composite enzyme against drug-resistant bacteria. The two-dimensional layered structure of the montmorillonite is used to anchor the active components of vanadium and manganese, so that the highly dispersed active sites and multi-enzyme synergistic catalysis are realized, and the generation rate of active oxygen is significantly improved. The obtained composite enzyme has high killing capacity for drug-resistant bacteria and good biocompatibility, and can be used for preparing biomedical antibacterial materials, antibacterial materials against drug-resistant bacterial infection or non-antibiotic antibacterial materials.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

The application discloses a strain of macrolide antibiotic high-efficiency degradation fungus Trichoderma asperellum TS7-1 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the Trichoderma asperellum TS7-1 is CGMCC No.41372. The strain Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the application has high-efficiency degradation capacity for various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), and the removal rates of the three antibiotics are all above 85% within 36 hours. The high-concentration antibiotic tolerance, degradation rate and degradation spectrum of the Trichoderma asperellum TS7-1 are obviously superior to those of other strains in the prior art. The Trichoderma asperellum TS7-1 is directly separated from a natural soil body without antibiotic pollution, has no hidden danger of animal and plant pathogenicity, and has no microbial toxicity to degradation products of the macrolide antibiotics, so that secondary pollution is avoided, and excellent environmental safety is achieved.

The invention discloses a non-antibiotic small-molecule inhibitor of clostridium difficile toxin B and a screening method of the non-antibiotic small-molecule inhibitor. According to the method, a plurality of broad-spectrum small-molecule inhibitors targeting all TcdB receptor binding interfaces at the same time are found through virtual screening and a multi-stage calculation strategy, and the inhibition effect of the broad-spectrum small-molecule inhibitors is verified by combining cell experiments; a lead compound and an action mechanism theoretical support are provided for development of non-antibiotic anti-CDI drugs, and a screening strategy and a screening result can also provide a theoretical basis and an experimental basis for development of a next-generation precise anti-CDI therapy.

This invention discloses a fully human monoclonal antibody Hm0699 against Staphylococcus aureus α-hemolysin and its applications. The antibody comprises a heavy chain and a light chain. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the heavy chain are shown in SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7; the amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the light chain are shown in SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10. This antibody can specifically bind to Staphylococcus aureus α-hemolysin and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections. It represents an important direction in the research field of "non-antibiotic" treatment of methicillin-resistant Staphylococcus aureus infections and control of drug resistance development.

The present application relates to the technical field of biological medicine, in particular to an antibody against staphylococcus aureus enterotoxin B and application thereof. The heavy chain variable region of the antibody provided in the present application comprises CDR sequences as shown in SEQ ID NO. 1-3, and the light chain variable region comprises CDR sequences as shown in SEQ ID NO. 9-11. The antibody has high affinity and can specifically bind to staphylococcus aureus SEB, can block the combination of SEB and MHC II / TCR, significantly inhibit cytokine storm, and exhibit dose-dependent protection effect in the MRSA systemic infection model, and can be used for treating, preventing or diagnosing staphylococcus aureus infection, and provides a non-antibiotic therapy solution for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health value.

The application provides a high-temperature-resistant and antibacterial sputum suction catheter and a preparation method thereof, and belongs to the technical field of medical devices. The preparation method comprises the following steps: modifying chitosan by treating quaternary ammonium salt chitosan with chitosanase to obtain modified chitosan, reacting polytetrahydrofuran, polyethylene glycol and diisocyanate to obtain a prepolymer, reacting the prepolymer, dimethylol propionic acid and the modified chitosan to obtain a polyurethane prepolymer, mixing modified silane and the polyurethane prepolymer to obtain a mixture, and extruding the mixture to obtain the high-temperature-resistant and antibacterial sputum suction catheter. In the application, the hydrophilic groups in the modified silane and the polyurethane polymer can reduce the friction of the surface of the sputum suction catheter and reduce the injury to the vascular endothelium. In addition, the quaternary ammonium salt structure in resveratrol and the modified chitosan can jointly destroy the metabolism of bacteria to achieve good bacteriostatic effect, and the combined non-antibiotic antibacterial strategy can delay the generation of drug-resistant bacteria.

This invention relates to filamentous fungal strains belonging to the phylum Ascomycota, excluding fungi belonging to the class Yeastae, wherein the gene encoding arginine permease ( CAN1 The strain or its variants or orthologs have been knocked out. This invention also relates to various uses of the strain, and genetic modification methods that allow for obtaining strains according to the invention. This invention also relates to the use of L-canavanine as a selective marker for transformants, wherein the gene encoding arginine permease (… CAN1 (or its variants or orthologs have been knocked out.)

The invention discloses an application of pranlukast in preparing a medicine for resisting clostridium difficile infection. A small-molecule inhibitor aiming at a toxin B (TcdB) receptor binding domain is screened by adopting an artificial intelligence auxiliary method. The research finds that the pranlukast has very high affinity (-35 kcal / mol) with TcdB. In-vitro experiment results show that pranlukast has no toxic effect on cells, but can obviously inhibit the cytotoxic effect induced by TcdB. After the I-EV-P is wrapped by EV (I-EV) from intestinal epithelial cells, the I-EV-P can remarkably recover the body weight of the gerbil, the survival rate reaches up to 100%, and the I-EV-P can also reduce the TcdB load after challenge of clostridium difficile and relieve intestinal tract lesions. The invention proves that pranlukast has excellent characteristics for the first time, is a promising non-antibiotic small molecular therapeutic agent, and can relieve pathological injury induced by TcdB and relieve infection of clostridium difficile.

The invention discloses an oral medicine containing sodium dehydroacetate, which is used for treating helicobacter pylori infection. In order to solve the problems of antibiotic resistance and gastrointestinal tract microecological disorder caused by the existing quadruple therapy, free molecules of the medicine disclosed by the invention under the gastric acid condition have strong lipophilicity, can efficiently penetrate through a gastric mucous layer and bacterial cell membranes, and can cause bacterial energy depletion death by blocking tricarboxylic acid cycle and energy metabolic centers such as succinate dehydrogenase. Animal experiments prove that the curative effect of reducing Hp colonization is equivalent to or even better than that of quadruple therapy. As a non-antibiotic bacteriostatic agent, the product has the advantages that drug resistance is not easy to generate due to multi-target action, normal intestinal flora is not damaged, flora imbalance and secondary infection are effectively avoided, and the safety is obviously improved.

The invention discloses pacific oyster galactose / rhamnose binding lectin CGL-1 recombinant protein as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In a diabetic rat model, the CGL-1 recombinant protein can significantly promote the healing of MRSA infectious wounds, and the healing rate reaches 92.44%-94.51%. Histological analysis shows that inflammatory cell infiltration of a wound surface of a CGL-1 treatment group is reduced, collagen deposition is increased, neovascularization is good, and a good healing effect is shown. In addition, the bacterial quantity of a wound surface of a CGL-1 treatment group is obviously lower than that of a model group, and the bacterial quantity is respectively reduced by 25.3%-88.55% and 68.45%-95.83% on the fifth day and the thirteenth day. The results show that the CGL-1 lectin protein has the potential of serving as a novel non-antibiotic therapeutic agent, can be used for treating diabetes infected wounds, and provides a new thought for application of marine biological resources in the field of wound healing.